Radiotherapy-immunity lncRNA model predicts lung adenocarcinoma prognosis and treatment outcome and distinguishes between hot and cold tumors
Abstract Background There are many prognostic markers for lung adenocarcinoma (LUAD). However, studies on the prognosis of LUAD by radiotherapy immune-related long noncoding RNAs (lncRNAs) are extremely rare. Methods We have compiled 1121 radiotherapy susceptibility differential genes and 6195 immun...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-04-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02184-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849734768497786880 |
|---|---|
| author | Lingfan Xiong Jing Guo Jingjun Lv Wenhao Guo Tingting Qiu |
| author_facet | Lingfan Xiong Jing Guo Jingjun Lv Wenhao Guo Tingting Qiu |
| author_sort | Lingfan Xiong |
| collection | DOAJ |
| description | Abstract Background There are many prognostic markers for lung adenocarcinoma (LUAD). However, studies on the prognosis of LUAD by radiotherapy immune-related long noncoding RNAs (lncRNAs) are extremely rare. Methods We have compiled 1121 radiotherapy susceptibility differential genes and 6195 immune-related genes. After that, we screened radiotherapy-immunity lncRNAs associated with proliferation by co-expression, univariate, least absolute shrinkage selection operator regression (LASSO), and multivariate analysis of variance. Finally, we constructed a prognostic model based on 6 lncRNAs, and verified the accuracy of the predictive model by ROC and C index. In addition, we used the constructed scoring model to analyze the model's association with the characteristics of immune cell infiltration, immune checkpoint and drug sensitivity. Finally, the whole sample was divided into 2 clusters to further distinguish hot and cold tumors. Results We constructed a risk score model built on 6 prognostically relevant lncRNAs. Patients were categorized into high-risk and low-risk patients based on median scores in the Train group. We found that people in the high-risk group had a lower survival rate than those in the low-risk group. However, those in the high-risk group were more sensitive to chemotherapy, targeted drugs and also more sensitive to immunotherapy drugs. Based on the line graphs of T, N, Age, Stage and Risk, the corresponding scores can be summed up to visualize the survival rate of patients at 1, 3 and 5 years. Gene set enrichment analysis (GSEA) suggested that radiotherapy-immunity-related lncRNA might be related to pathways such as cell cycle, T cell receptor signaling pathway. It is noteworthy that in our study, cluster 1 was considered to be a hot tumor more sensitive to immunotherapy. Conclusion In summary, we constructed a risk score model built on six radiosensitivity and immune-related lncRNAs, which is expected to be a potential predictive biomarker for radiosensitivity and LUAD prognosis. |
| format | Article |
| id | doaj-art-c85513fec5b24c6c821578286dd5e87b |
| institution | DOAJ |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-c85513fec5b24c6c821578286dd5e87b2025-08-20T03:07:43ZengSpringerDiscover Oncology2730-60112025-04-0116111810.1007/s12672-025-02184-0Radiotherapy-immunity lncRNA model predicts lung adenocarcinoma prognosis and treatment outcome and distinguishes between hot and cold tumorsLingfan Xiong0Jing Guo1Jingjun Lv2Wenhao Guo3Tingting Qiu4Department of Oncology, China Resources & Wisco General Hospital, Wuhan University of Science and TechnologyDepartment of Oncology, China Resources & Wisco General Hospital, Wuhan University of Science and TechnologyDepartment of Anal Surgery, China Resources & Wisco General Hospital, Wuhan University of Science and TechnologyDepartment of Oncology, China Resources & Wisco General Hospital, Wuhan University of Science and TechnologyJiangxi Clinical Research Center for Cancer, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical CollegeAbstract Background There are many prognostic markers for lung adenocarcinoma (LUAD). However, studies on the prognosis of LUAD by radiotherapy immune-related long noncoding RNAs (lncRNAs) are extremely rare. Methods We have compiled 1121 radiotherapy susceptibility differential genes and 6195 immune-related genes. After that, we screened radiotherapy-immunity lncRNAs associated with proliferation by co-expression, univariate, least absolute shrinkage selection operator regression (LASSO), and multivariate analysis of variance. Finally, we constructed a prognostic model based on 6 lncRNAs, and verified the accuracy of the predictive model by ROC and C index. In addition, we used the constructed scoring model to analyze the model's association with the characteristics of immune cell infiltration, immune checkpoint and drug sensitivity. Finally, the whole sample was divided into 2 clusters to further distinguish hot and cold tumors. Results We constructed a risk score model built on 6 prognostically relevant lncRNAs. Patients were categorized into high-risk and low-risk patients based on median scores in the Train group. We found that people in the high-risk group had a lower survival rate than those in the low-risk group. However, those in the high-risk group were more sensitive to chemotherapy, targeted drugs and also more sensitive to immunotherapy drugs. Based on the line graphs of T, N, Age, Stage and Risk, the corresponding scores can be summed up to visualize the survival rate of patients at 1, 3 and 5 years. Gene set enrichment analysis (GSEA) suggested that radiotherapy-immunity-related lncRNA might be related to pathways such as cell cycle, T cell receptor signaling pathway. It is noteworthy that in our study, cluster 1 was considered to be a hot tumor more sensitive to immunotherapy. Conclusion In summary, we constructed a risk score model built on six radiosensitivity and immune-related lncRNAs, which is expected to be a potential predictive biomarker for radiosensitivity and LUAD prognosis.https://doi.org/10.1007/s12672-025-02184-0Tumor microenvironmentCancer immunotherapyLong noncoding RNAsLung adenocarcinomaRadiotherapyPrognostic biomarker |
| spellingShingle | Lingfan Xiong Jing Guo Jingjun Lv Wenhao Guo Tingting Qiu Radiotherapy-immunity lncRNA model predicts lung adenocarcinoma prognosis and treatment outcome and distinguishes between hot and cold tumors Discover Oncology Tumor microenvironment Cancer immunotherapy Long noncoding RNAs Lung adenocarcinoma Radiotherapy Prognostic biomarker |
| title | Radiotherapy-immunity lncRNA model predicts lung adenocarcinoma prognosis and treatment outcome and distinguishes between hot and cold tumors |
| title_full | Radiotherapy-immunity lncRNA model predicts lung adenocarcinoma prognosis and treatment outcome and distinguishes between hot and cold tumors |
| title_fullStr | Radiotherapy-immunity lncRNA model predicts lung adenocarcinoma prognosis and treatment outcome and distinguishes between hot and cold tumors |
| title_full_unstemmed | Radiotherapy-immunity lncRNA model predicts lung adenocarcinoma prognosis and treatment outcome and distinguishes between hot and cold tumors |
| title_short | Radiotherapy-immunity lncRNA model predicts lung adenocarcinoma prognosis and treatment outcome and distinguishes between hot and cold tumors |
| title_sort | radiotherapy immunity lncrna model predicts lung adenocarcinoma prognosis and treatment outcome and distinguishes between hot and cold tumors |
| topic | Tumor microenvironment Cancer immunotherapy Long noncoding RNAs Lung adenocarcinoma Radiotherapy Prognostic biomarker |
| url | https://doi.org/10.1007/s12672-025-02184-0 |
| work_keys_str_mv | AT lingfanxiong radiotherapyimmunitylncrnamodelpredictslungadenocarcinomaprognosisandtreatmentoutcomeanddistinguishesbetweenhotandcoldtumors AT jingguo radiotherapyimmunitylncrnamodelpredictslungadenocarcinomaprognosisandtreatmentoutcomeanddistinguishesbetweenhotandcoldtumors AT jingjunlv radiotherapyimmunitylncrnamodelpredictslungadenocarcinomaprognosisandtreatmentoutcomeanddistinguishesbetweenhotandcoldtumors AT wenhaoguo radiotherapyimmunitylncrnamodelpredictslungadenocarcinomaprognosisandtreatmentoutcomeanddistinguishesbetweenhotandcoldtumors AT tingtingqiu radiotherapyimmunitylncrnamodelpredictslungadenocarcinomaprognosisandtreatmentoutcomeanddistinguishesbetweenhotandcoldtumors |